The CSF Aβ42/P-tau or Aβ42/Aβ40 ratios with the addition of total tau and phosphorylated tau measurements have been proven more reliable markers for the presence and progression of cognitive decline from MCI to overt AD than CSF Aβ42 alone [210,211,212]. The gene discussed is MAPT; the disease is Alzheimer disease.